# Retatrutide

> Retatrutide is an investigational triple hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors. In mid-stage clinical trials it produced some of the largest average body-weight reductions reported for an injectable weight-management agent to date. It is not yet approved by regulatory agencies and remains under study in late-stage clinical trials. Research to date is limited to controlled trial populations, and long-term safety and outcome data are still being gathered. It should not be considered an approved treatment, and any use outside of a clinical trial or licensed prescriber's supervision is not supported by current evidence.

- URL: https://www.lifeconverted.com/peptides/retatrutide
- Also known as: LY3437943
- Primary category: Weight Management
- Effectiveness rank: #1 in Weight Management
- Evidence level: Moderate evidence
- Route: Subcutaneous
- Dose range: 2-12 mg
- Dose tiers: low 2 mg; moderate 4 mg; high 12 mg
- Half-life: Approximately 17 days in trial pharmacokinetic reports, consistent with once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous use with gradual up-titration over several months in trial protocols on, Not established outside of trial discontinuation; no standard off-cycle described in published research off (Dose increases are typically spaced several weeks apart to reduce gastrointestinal side effects.)
- Storage: Refrigerate at 2-8°C (36-46°F); protect from light; do not freeze. Follow the specific handling instructions provided with any trial or pharmacy-dispensed product.

## Mechanism of action

Retatrutide binds and activates three separate incretin-related receptors: GLP-1, GIP, and the glucagon receptor. Combined GLP-1/GIP activity slows gastric emptying and increases satiety signaling, while added glucagon receptor activity is believed to raise energy expenditure and support hepatic fat metabolism. This triple-receptor approach is proposed to produce greater metabolic effect than single- or dual-receptor agonists, though the relative contribution of each receptor pathway in humans is still being characterized.

## Reported benefits

- Associated with substantial reductions in body weight in clinical trial participants
- May improve markers of glycemic control
- Combined incretin/glucagon activity may support fat oxidation
- Once-weekly dosing schedule in studies to date

## Reported side effects

- Nausea, vomiting, and diarrhea, especially during dose escalation
- Decreased appetite
- Potential for gallbladder-related events
- Injection-site reactions
- Theoretical thyroid C-cell risk based on the GLP-1 drug class

## Common protocols

- Trial-based titration schedules starting at low doses and increasing every 4 weeks
- Weekly subcutaneous injection with rotation of injection sites

## Stacking notes

Not established; combining with other incretin-based agents is not supported by published research and may increase gastrointestinal side effects.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer